Formulation, development and characterization of frovatriptan succinate in situ gel for nasal administration

Abstract

Introduction: One of the most common conditions in the world is migraine. This is the second most common reason why non-manual workers miss work for a short time. This study created new in situ-gel forms of FVT for intranasal administration. These forms help the drug pass through the nasopharyngeal barrier more easily and stay in the nose cavity longer.

Materials and Methods: A thermoreversible, mucoadhesive in situ intranasal gel was made with frovatriptan succinate. The mucoadhesive properties of the gel make it stay in the nasal cavity longer, and the thermoreversible properties make it easier to work with and give.

Results: The best amount of carbopol 934 for mucoadhesive strength and the right temperature for the phase change is 0.2% w/v. Carbopol makes it easier for the drug to be absorbed and works better. This mixture did not do a lot of damage to the nasal membranes. Conclusion: The findings of this study support using Frovatriptan succinate as a new mucoadhesive in situ intranasal gel to treat migraines.